BS Pharm Korea Strengthens INHILO+ Market Development Through Distribution and Clinical Collaboration

BS Pharm Korea is strengthening the market development of its INHILO+ skin booster in South Korea. The company has initiated domestic distribution in partnership with Dongkook Pharmaceutical and is advancing the product's market position through clinical data and a clinical evaluation program.

The dual-molecular HA skin booster's market entry is supported by scientific evidence and expanded distribution channels. BS Pharm Korea aims to increase product awareness and accessibility within the South Korean market.

The collaboration with Dongkook Pharmaceutical is expected to enhance the distribution network for INHILO+, making the product more readily available to healthcare professionals and consumers. The clinical evaluation program serves to demonstrate the product's efficacy and safety in the local setting.

BS Pharm Korea's strategy focuses on establishing INHILO+ as a significant player in the South Korean aesthetic dermatology market. This effort is driven by the increasing importance of scientific validation and robust distribution.